AP NEWS

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Jianpu, Nektar, and Honeywell and Encourages Investors to Contact the Firm

December 3, 2018

NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Jianpu Technology Inc., Nektar Therapeutics, and Honeywell International Inc. Stockholders have until the deadlines listed below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Jianpu Technology Inc. (NYSE: JT)

Class Period: Pursuant and/or traceable to the initial public offering on or about November 17, 2017

Lead Plaintiff Deadline: December 24, 2018

The complaint alleges that the Company’s IPO offering materials contained inaccurate statements of material fact and/or omitted material information required to be disclosed in order to make such statements not misleading, including failure to disclose that the China Banking Regulatory Commission and three other Chinese regulators had issued rules in 2016 requiring peer-to-peer lending companies to appoint qualified banking institutions as custodians and disclose their use of deposits. On November 21, 2017, news outlets reported that China’s Financial Stability and Development Committee (“FSDC”) had issued an urgent notice to provincial governments urging them to suspend regulatory approval of new internet micro-loan companies. Following this news, Jianpu’s shares fell over 38% in three days and closed at $4.90 per share on November 24, 2017.

To learn more about the Jianpu class action go to: http://bespc.com/jt/.

Nektar Therapeutics (NASDAQ: NKTR)

Class Period: November 11, 2017 - October 2, 2018

Lead Plaintiff Deadline: December 31, 2018

The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding the company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) prior studies which attempted to pegylate IL-2 failed; (ii) NKTR-214’s extended half-life was unlikely to result in efficacy and created additional high-dosing safety concerns; (iii) NKTR-214 was less effective than IL-2 alone; (iv) the combination of NKTR-214 with nivolumab has not yet demonstrated significant positive results; and (v) as a result, Nektar’s public statements as set forth above were materially false and misleading at all relevant times.

To learn more about the Nektar class action go to: https://bespc.com/nktr/.

Honeywell International Inc. (NYSE: HON)

Class Period: February 9, 2018 - October 19, 2018

Lead Plaintiff Deadline: December 31, 2018

The complaint alleges that throughout the Class Period, defendants made materially false and misleading statements regarding Honeywell’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Honeywell’s Bendix asbestos-related liability was greater than initially reported; (ii) the Company maintained improper accounting practices in connection with its Bendix asbestos-related liability; and (iii) as a result, Honeywell’s public statements were materially false and misleading at all relevant times.

To learn more about the Honeywell class action go to: http://bespc.com/hon/.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

ContactsBragar Eagel & Squire, P.C.Brandon Walker, Esq.Melissa Fortunato, Esq.(212) 355-4648 investigations@bespc.comwww.bespc.com

AP RADIO
Update hourly